As shown in Figure 1, compared with the control group, the level of blood glucose significantly increased in the STZ-treated group (DCM group) (29.68 ± 2.43 mM versus 7.98 ± 1.12 mM, p < 0.001), whereas body weight and serum insulin level were significantly lower in the DCM group (body weight: 23.14 ± 1.24 g versus 29.5 ± 1.14 g, p < 0.001; serum insulin: 29.27 ± 2.37 mIU/ml versus 36.6 ± 3.94 mIU/ml, p < 0.05). Here, INS is linked to familial dilated cardiomyopathy.